Dr. Agarwal on Candidates for Docetaxel Versus Abiraterone and Prednisone

Neeraj Agarwal, MD, associate professor, Division of Oncology, Department of Medicine, University of Utah School of Medicine, Huntsman Cancer Institute, discusses how to determine which patient with prostate cancer is a candidate for docetaxel versus abiraterone acetate (Zytiga) and prednisone.

If a patient has a high-volume of disease, docetaxel is most likely the best option, according to Agarwal. However, if a patient has a low-volume disease, Agarwal would be more inclined to offer abiraterone and prednisone.

Research still needs to be conducted to develop biomarkers to better determine the treatment for these patients, states Agarwal.